THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces Public Offering of Common Stock and Warrants
December 16, 2021 16:01 ET | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it intends to offer and...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces Support of EB Research Partnership's Venture Into Cures Event to Raise Awareness for Education and Research of Epidermolysis Bullosa
November 18, 2021 07:30 ET | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its sponsorship of the second...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces Presentation on Pivotal Transpher A Study of ABO-102 in MPS IIIA at the 14th ICIEM Conference
November 17, 2021 07:30 ET | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that information about the...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces Participation at the Jefferies London Healthcare Conference
November 16, 2021 07:30 ET | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D.,...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Reports Third Quarter Financial Results
November 15, 2021 07:45 ET | Abeona Therapeutics Inc.
Phase 3 VIITAL™ study on track to complete enrollment in first quarter 2022 with final patients identified and under screening Added gene therapy and biopharmaceutical industry veterans to regulatory...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics to Present at Jefferies Gene Therapy/Editing Summit
October 21, 2021 07:30 ET | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D.,...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses
October 13, 2021 07:30 ET | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced two presentations of previously...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Appoints Gene Therapy Quality Leader Jon Voss as Vice President, Head of Quality
October 12, 2021 07:30 ET | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Jon Voss as...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) Filings
September 21, 2021 16:01 ET | Abeona Therapeutics Inc.
Steven H. Rouhandeh to retire as Chairman of the Board; Michael Amoroso appointed Chairman of the Board Vishwas Seshadri, Ph.D., M.B.A. to become Chief Executive Officer Brendan M. O’Malley,...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics to Present at Upcoming Investor Conferences
September 07, 2021 07:30 ET | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that members of the company’s...